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Cannabinoids encompass natural cannabis and synthetic cannabinoids.  While the 
synthetic cannabinoids interact with the same endogenous system as cannabis, their 
effects are quite different and poorly understood. In addition to psychological effects that 
trigger their use, these substances are linked to cardiovascular morbidity.  To assess the 
cardiovascular effect of synthetic cannabinoids, we first tested the hypothesis that 
intravenous administration of a synthetic cannabinoid would increase blood pressure in 
conscious rats. Second, we tested the hypothesis that the sympathetic nervous system is 
involved by injecting a ganglion blocker to see if the cardiovascular response from 
synthetic cannabinoids would be blocked. Third, we tested the hypothesis that the 
hypothalamic paraventricular nucleus is involved by doing immunohistochemistry to 
check for cFos fluorescence.  
We found that synthetic cannabinoid use peaked with 7,000 calls to poison 
control centers in 2011 and has stabilized between 1,000-2,000 calls per year in the US.  
In humans, cardiovascular effects account for approximately 40% of adverse responses to 
synthetic cannabinoids.  The most frequently reported being tachycardia (50%) and 
 
hypertension (20%).  To test our hypothesis, Sprague Dawley rats were fitted with 
chronic indwelling arterial and venous catheters to record blood pressure and heart rate.  
Conscious rats were given intravenous injections of vehicle (20% cyclodextrin) then 
incremental doses of the synthetic cannabinoid, WIN 55, 212-2 (25, 50, 100 ug/kg + 0.2 
ml saline flush). We observed that injection of WIN resulted in rapid onset dose 
dependent increases in blood pressure and heart rate that peaked at approximately 18+/-6 
mm Hg and 90+/-15 bpm.  We also observed that interruption of autonomic function via 
ganglion blockade abolished the pressor effect of WIN. Lastly, we also used 
immunohistochemistry to assess the role of the PVN in the response to WIN. 
Collectively, the data are consistent with the view that synthetic cannabinoids, such as 
WIN, increase blood pressure and heart rate via autonomic mechanisms that may be 
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Cardiovascular Disease Statistics 
 
Cardiovascular diseases: including coronary heart disease, heart failure, stroke, 
and hypertension, make up the number one major cause of death in the United States, 
affecting 440, 460 males, and 418, 665 females per year (Virani et al., 2021). Cancer, 
accidents, chronic lower respiratory disease, Alzheimer’s disease, and diabetes all cause 
significantly fewer deaths in comparison (Figure 1). Between the ages of 20-39, 29.8% of 
males, and 17.2% of females have some form of cardiovascular disease. At the middle 
age bracket, 40-59 years old, over 50% of both males and females have some form of 
cardiovascular disease (Virani et al., 2021, pp. e340-e342). As of 2017, there are over 























Hypertension, or dysregulation of blood pressure, is an underlying causative 
factor that promotes all of these cardiovascular diseases. Hypertension affects 47.3% of 
adults in the United States. While approximately 11% of individuals die due to high 
blood pressure, dysregulation of blood pressure is a contributing factor to other diseases 
such as coronary artery disease, heart failure, kidney disease, and stroke that also have a 
substantial mortality risk. For example, coronary heart disease is the primary cause of 
death (42.1%) in the United States (Virani et al., 2021). About every 39 seconds, 
someone in the United States has a heart attack. Hypertension is highly prevalent. 
Globally, 1.13 billion people suffer from hypertension, 26% of the world’s population. 
About 75% of those individuals’ live-in low-income countries (Organization, 2021). Less 
than 1 out of 5 people who are diagnosed with hypertension have it controlled, high 
systolic BP is the number one risk factor for years of life lost, globally in 2019 (Virani et 
 
 




al., 2021). Since cardiovascular disease is so prevalent, we know that dysregulation of 
blood pressure is an important factor in these diseases, factors that increase blood 
pressure can have deleterious effects.  We are interested in the cardiovascular response to 
synthetic cannabinoids.  
Synthetic Cannabinoids (Nomenclature/History) 
Synthetic Cannabinoids, commonly called “synthetic marijuana” are considered 
“designer drugs”, as they are created in a lab and act on the same receptors as THC in 
marijuana, however, they bind to those receptors more strongly than THC, produce much 
stronger and different effects, and do not show up on a standard drug test. Synthetic 
cannabinoids are part of a group of drugs called novel psychoactive substances (NPS). 
Non classical synthetic cannabinoids have no medical benefit at present and have a high 
potential for abuse. Consumers can buy synthetic cannabinoids in convenience stores, 
from individual drug dealers, or online as incense or natural herbal products. They are 
sold under a number of brand names, including K2, Spice, and others.  Cannabinoids is a 
generic name that encompasses both naturally occurring cannabis (marijuana) delta 9 
tetrahydrocannabinol, but also synthetic cannabinoids, which can be either classical, with 
a structure similar to THC such as dronabinol and nabilone, which are cannabis related, 
or the chemically derived “non-classical” synthetic cannabinoids which have a wide 
variety of chemical structures, as they are entirely derived chemically and synthesized in 
labs, and while they interact with the same systems in the body, they have very different 
effects.   
The endocannabinoid system is involved in controlling many different processes 
in the body: cognitive processing, behavior, memory, appetite, pain, motor functioning, 
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immune functioning, gastrointestinal functionality, nervous system, and cardiovascular 
health (Le Boisselier, Alexandre, Lelong-Boulouard, & Debruyne, 2017). There are three 
identified cannabinoid receptor ligands. Endocannabinoids (anandamide), naturally 
occurring cannabinoids-phytocannabinoids (delta-9-tetrahydrocannabinol, THC) and then 











Figure 3 shows a variety of adverse effects to 3 different types of synthetic 
cannabinoids. One of the things I found striking was the fact that people take it for its 
psychological effects, but adverse psychological responses only account for about 30% of 
the effects, and the cardiovascular adverse responses are far more prevalent than any of 
the other effects.  
The first synthetic cannabinoids were created for pharmacological research 
purposes to study the endocannabinoid system. Researchers found a way to separate the 
THC from the plant to use for therapeutic medicinal treatments. In the 1960s, 
 




neuroscience research transitioned to searching for analgesic and anti-inflammatory 
properties of cannabinoid receptor agonists (Lindsay & White, 2012). A majority of SCs 
previously synthesized for research purposes were named after the scientist or 
corporation that was involved in their synthesis. Pfizer, in 1970, created their own non-
classical cannabinoid, called the CP series, after Charles Pfizer to be utilized for 
recreational purposes. In 1995, JWH compounds contained in SCs are named after John 
W. Huffman, the Clemson University professor that synthesized it to study its 
pharmaceutical effects on the brain (Brents & Prather, 2014) Whereas the AM 
compounds are named after a renowned scientist known as Alexandros Makriyannis of 
Northeastern University. Furthermore, HU compounds are affiliated to Hebrew 
University, created by chemist, Raphael Mechoulam based in Jerusalem, basing HU’s 
compound on the structure of THC (Heath, Burroughs, Thompson, & Tecklenburg, 
2012). WIN  was developed by the research company, Sterling-Winthrop through their 
research on pravadoline by conformationally restraining aminoalkylindole analogs, 
however, they dropped their research when they discovered WIN was cannabimetic 
(Wiley, Marusich, Huffman, Balster, & Thomas, 2011). The classification of SCs for 
recreational use was intended to help advertise and market products containing SC. For 
instance, AKB-48 denotes the title of a South Korean girl rock band, while XLR-11 was 
associated with the first USA-created liquid fuel rocket used by aircrafts. Currently, a 
significant percentage of synthetic cannabinoids are given names that derive from their 
innate structural compounds, that is, their core, tail name, linker, and associated groups.  
However, using the term ‘synthetic marijuana’ to refer to products with synthetic 
cannabinoids is debatable and a mistake according to Lewis Nelson, a renowned 
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toxicologist in the United States (Ibrahim, Al-Saffar, & Wannenburg, 2014). Nelson 
argues that products that contain synthetic cannabinoids are highly variable and 
significantly more potent than marijuana, and as long as marijuana is considered a 
criminalized drug and not regulated, synthetic cannabinoids, like “spice” and “K2” will 
be rampantly available as ‘legal marijuana’ on the market, causing toxic exposures and 
clinical consequences (Lapoint et al., 2011; Takematsu et al., 2014). Thus, given that the 
term ‘synthetic’ does not denote any known plant, using the phrase synthetic cannabinoid 
seems suitable. Synthetic cannabinoids are known by many street names such as K2, 
Bombay Blue, and Black Mamba. Fanatics of products containing synthetic cannabinoids 
in Spanish nations like Chile, refer to these products as ‘cripy’. In convenience stores and 
smoke shops, products with synthetic cannabinoids are referred to as “herbal incense” or 
“herbal smoking blends,” with colorful packaging, often labelled as incense or potpourri 
often labeled with “not for human consumption, keep out of reach of children” (Zawilska 
& Wojcieszak, 2014).  
Epidemiology 
A good deal of epidemiological data indicates that synthetic cannabinoids have a 
history of substantial use and impact on health.  From the findings, it was determined that 
the drug is highly abused in the U.S. Military and Navy, and for civilians, the abuse is 
common among adolescents. Synthetic cannabinoids are a diverse group of compounds 
designed to mimic cannabis.  While not as frequent as cannabis, their use is still quite 
widespread. In 2011, 30 Airmen at an Air Force Base in Oklahoma, were discharged for 
spice use. In October of the same year, 64 Sailors were busted for spice use aboard the 
carrier, while, one month later, 28 more Sailors were caught on a different carrier. Spice 
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use led to the expulsion of 16 men from the Naval Academy in 2011, followed by 14 
Coast Guard Academy cadets in January 2012.  Between 2011-2012, over 150 personnel 
were apprehended for synthetic cannabinoid use in five separate incidents in different 
military branches which shows the extent of the problem among the disciplined forces 
(White, 2017). 
Synthetic cannabinoid use is also highly prevalent in the general public.  Kelley et 
al., 2013 conducted a field-based study in New York City nightclubs in 2012, finding that 
8.2% of 1749 adults with a mean age of 26.4, 55% of those being male, reported using 
synthetic cannabinoids in the past year (Kelly et al., 2013).Whereas, in (Winstock et al., 
2011), a 2011 study on synthetic cannabinoid prevalence in the UK, 12.6% of 2700 
adults reported using a synthetic cannabinoid in the past year. According to NIH, in 2012, 
11% of American high school seniors had used synthetic cannabinoids in the past year 
the majority being white males from urban locations (Gunderson, Haughey, Ait-Daoud, 
Joshi, & Hart, 2014). In this study, the researchers also found that the proportion of 
adolescent males who engaged in synthetic cannabinoid use was 70%. In 2011, 28, 531 
emergency room visits, were linked to synthetic cannabinoid use, out of those, 78% were 
between the ages of 12-29. In a worldwide survey of nearly 15,000 participants, 17% 
reported synthetic cannabinoid use (Singh et al., 2018). Synthetic cannabinoid use is 
associated with serious consequences. In Mississippi from April through May of 2015 
approximately 1200 emergency room visits, and 17 deaths were attributed synthetic 
cannabinoids (White, 2017). In 2015, the American Association of Poison Centers 
identified 3500 calls related to synthetic cannabinoid use, a dramatic 299% increase from 
just 6 months prior in 2014 (LT George Loeffler, 2012). The increase was immense and 
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reveals the problem related to the illegal and unprescribed use of the substance. In 2016, 
there were 130 emergency department visits due to synthetic cannabinoid use in New 
York City in a single week in July 2016 (White, 2017). According to a study done by 
Gloria Martz, between 2014 and 2016, 49.8% of 429 adolescents between the ages of 13-
17 were admitted to a Children’s Recovery Center in Oklahoma for synthetic cannabinoid 
use. 22.4% of these children reported being daily SC users. Martz, in this same study, 
discussed that young individuals are at an increased risk for using synthetic cannabinoid 
products, as they are relatively inexpensive, easily available, known to produce higher 
subjective effects, and difficult to detect on drug tests (Martz, Tankersley, Mekala, & 
Motiwala, 2018). In summary, the current epidemiological data indicate that synthetic 
cannabinoids are used relatively extensively.  There is also a substantial body of data 














Figure 4. Data derived from: (Roehler, Hoots, & Vivolo-Kantor, 2020) 
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Figure 4 shows the regional disparity as a trend over time on the proportion of ER 
visits related to Synthetic Cannabinoid exposure. Note the regional differences with a 
rather stable national trend (the green line) from 2016- 2019. On the West (orange line), 
you can see the biggest decline in exposure, however, in the Midwest (the black line) 
there is a recent upwards trajectory in exposure.  
Effects of Synthetic Cannabinoids in Humans 
While synthetic cannabinoids interact with the same endogenous system as 
cannabis, their effects are quite different and poorly understood. As seen in Figure 3, 
synthetic cannabinoids adversely affect many physiological processes including 
gastrointestinal (7.4-13.8% of cases), psychiatric (26.2-29.6%), neurological (18.5-
44.4%) and the most commonly presenting affect is cardiovascular (40.9-44.4%). Serious 
adverse cardiovascular effects have presented following both acute and chronic synthetic 
cannabinoid use within case reports and clinical studies, resulting in stroke, arrythmias, 
cardiomyopathy, myocardial infarction, and cardiac arrest (Pacher, Steffens, Haskó, 
Schindler, & Kunos, 2018).In addition to psychological effects that trigger their use, in 
humans these substances may cause substantial cardiovascular morbidity including, 
increased heart rate and blood pressure which may contribute to deadly effects such as 
heart attacks (White, 2017).  It seems that the synthetic cannabinoids may activate the 
autonomic nervous system, however, how this happens is not yet understood.  
Unfortunately, there remains a lot of controversy surrounding how synthetic 


















Figure 5 shows data taken from multiple case studies, regarding the distribution of 
acute cardiovascular adverse events in patients using synthetic cannabinoids. the most 
predominant effects are related to increases in heart rate, blood pressure and cardiac 
arrhythmia. Patients have also presented with angina, which is indicative of disturbances 
in cardiac electrical activity and coronary ischemia, respectively.  
Cardiovascular Concerns of Excessive Uses of Synthetic Cannabinoids 
Researchers have suspected the excessive use of products containing synthetic 
cannabinoids for over five decades have resulted in adverse cardiovascular effects. 
However, the last decade has experienced a steady increase in reported frequencies of 
cardiovascular-related complications. A recent systematic review has concluded that 
 
 
Figure 5. Data compiled from: (Cohen & Weinstein, 2018; Davidson et al., 2017; 
Hermanns-Clausen et al., 2016; Jouanjus, Raymond, Lapeyre-Mestre, & Wolff, 





there is a positive correlation between excessive use of products containing synthetic 
cannabinoids and cardiovascular complications among patients in many hospitals across 
the United States (Hermanns-Clausen et al., 2016). To put this into perspective, the 
United Kingdom National Poisons Information Service has recorded that between 40-45 
percent of all synthetic cannabinoid-linked incidents are of a cardiovascular nature 
among youths and individuals in their early adult ages between 2006 and 2010 (Waugh et 
al., 2016). Moreover, the prevalence of cardiovascular-related difficulties grew from 
1.1% during 2006, to about 3.6% during 2010, whereas the death rate linked to those 
complications reached 25% by the end of 2010 (Heath et al., 2012). Synthetic 
Cannabinoid users who display these complications are often young males and, 
importantly, have no underlying or genetic link for cardiovascular conditions. Common 
cardiovascular difficulties of products containing synthetic cannabinoids range from mild 
to severe depending on the type of complication. A variety of cardiovascular related 
complications have been reported. 
Cerebrovascular Disease 
 Excessive use of products with synthetic cannabinoids leads to the early 
development of cerebrovascular disease among individuals in their early 20s, and patients 
undergoing cancer treatment procedures. Patients with cardiovascular conditions 
showcase symptoms such as neurological impairment and ischemic stroke as the most 
common adverse impact as a result of using products containing synthetic cannabinoids 
(Singh et al., 2018). Furthermore, a study conducted among a segment of an Australian 
population demonstrated that individuals aged between 18 and 44 years suffered from 
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ischemic events due to excessive use of products containing synthetic cannabinoids 
(Jouanjus et al., 2017; Wolff & Jouanjus, 2017). 
Chronic use and smoking of synthetic cannabinoids trigger cerebrovascular events 
that impact an individual’s cardiovascular condition. Some of the mechanisms that are 
linked to probable cerebrovascular dangers such as direct vasculo-toxic impacts, 
modifications in hemodynamics, and atrial fibrillation (Lindsay & White, 2012; White, 
2017). Also, temporary exposure to smoke produced by synthetic cannabinoid can trigger 
endothelial dysfunction among patients (Singh et al., 2018; Von Der Haar et al., 2016). A 
population review in US-based hospitals reveals that people with habitual smoking of 
products containing synthetic cannabinoids experience a three-fold increase in the 
possibility of developing intense cerebrovascular events (Hermanns-Clausen et al., 2016). 
Also, a case study series by the American Heart Association demonstrated that 
individuals with ischemic stroke are in danger of suffering a persistent stroke when they 
start re-using products containing synthetic cannabinoids (DeFilippis et al., 2020; Khan, 
Hanif, & Wilson, 2018; Wolff & Jouanjus, 2017). The male population in the United 
States is more at risk to suffer from cerebrovascular disease than women and the fact that 
males more commonly are the ones who smoke synthetic cannabinoids is concerning.  
Arrhythmias 
 Incessant usage of products with high concentrations of synthetic cannabinoids 
leads to severe cases of arrhythmias and a wide variation of electrical impacts that 
deteriorates an individual’s cardiovascular condition. These conditions include atrial 
fibrillation, asystole, and supraventricular tachycardia that intensifies an individual’s 
CVD situation (Al Fawaz et al., 2019). Additionally, high dosages of synthetic 
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cannabinoids caused increases in catecholamines, and the stimulation of cardiac beta-
adrenergic receptors may heighten the likelihood of a patient developing arrhythmias 
(Ozturk, Yetkin, & Ozturk, 2019). Atrial fibrillation is the most common form of 
arrhythmias among patients who use products containing synthetic cannabinoids (Pacher 
et al., 2018; White, 2017).  
The incessant use of synthetic cannabinoids triggers huge fluctuations in cardiac 
rhythms. The rhythm variations include sinus tachycardia, ectopic atrial, and ventricular 
fibrillation that often leads to sudden cardiac death among patients who are consistent 
users. Cardiac tachyarrhythmias are due to excessive use of synthetic cannabinoids 
causing the introduction of a hyperadrenergic state (Ozturk et al., 2018; Ozturk et al., 
2019; White, 2017). Further, a recent electrophysiology review to investigate the effects 
of excessive use of synthetic cannabinoid compounds reveals the prevalence of inducible 
and untimely ventricular contractions. Similarly, myocardial ischemia that occurs due to 
microvascular spasm in response to synthetic cannabinoid use may lead to severe 
dizziness, syncope, cardiac arrest, and eventually an abrupt cardiac death (Cohen & 
Weinstein, 2018).  
Cannabis Arteritis 
Cannabis vasculopathy is indistinguishable from thrombo-angiitis obliterans, 
however, it presents at an earlier age in those who consume both synthetic cannabinoids 
and tobacco (Ibrahim et al., 2014). Additionally, subacute and advanced ischemia for 
upper and lower limits impacted by arteritis may result in severe difficulties such as 
tissue necrosis with deteriorating effects when an individual uses synthetic cannabinoids 
(Ibrahim et al., 2014). Additional vascular difficulties of nonstop use of synthetic 
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cannabinoid products are migratory thrombophlebitis, renal artery segmentation, and 
vasculopathy concerning the occlusion of the primary retinal veins (Singh et al., 2018).  
Clinical Implications 
The two German investigators who smoked “Spice Diamond” experienced the 
acute effects due to smoking which included change in opinions and thinking, and dry 
mouth (White, 2017). According to their study, the use of synthetic cannabinoids causes 
tachycardia, impairment of mood and perception, anxiety, loss of concentration, paranoia, 
and then post use, extreme fatigue. The most common adverse events associated with the 
use of synthetic cannabinoids include agitation, drowsiness, vomiting, and other extreme 
effects which easily lead to death. Males who are over the age of 30 years were more 
likely to die and experience serious symptoms as compared to the female counterparts 
(Zaurova et al., 2016). The most common cardiovascular symptom associated with the 
use of synthetic cannabinoids include tachycardia with a heart rate of 90-170 beats every 
minute.  In addition, at least a third of the patients exhibited hypertension (Zaurova et al., 
2016). Hypokalemia, muscle pain, and acute psychosis were also some of the major 
symptoms that developed and last for several days. The typical psychotic and 
neurological effects include the drowsiness, paranoia, and euphoria which developed with 
continuous and use of synthetic cannabinoids. A study conducted between patients with 
exposure to synthetic cannabinoids and other patients who had smoked traditional 
marijuana revealed modified and altered mental status and cardiotoxicity of the 





Effects of Synthetic Cannabinoids in Rats 
Short term administration of these agents to anesthetized animals result in an 
overall decrease in blood pressure (Malinowska, Baranowska-Kuczko, & Schlicker, 
2012; Malinowska, Toczek, Pedzinska-Betiuk, & Schlicker, 2019; O'Sullivan, 2015). In 
contrast, research in conscious animals is more limited, but these agents appear to cause 
an increase in blood pressure (Ho & Gardiner, 2009; S.M. Gardiner, 2001; Schindler, 
Gramling, Justinova, Thorndike, & Baumann, 2017). Schindler (Schindler et al., 2017) 
saw increases in blood pressure with a series of synthetic cannabinoids. Gardiner (S.M. 
Gardiner, 2001) responses show dose dependent increases in blood pressure. However, 
both of these studies showed a decrease in heart rate. (Niederhoffer & Szabo, 1999) 
reported a decrease in blood pressure with WIN 55, 212-2 in conscious rabbits. 
Therefore, there remains considerable controversy regarding the effects of synthetic 
cannabinoids in cardiovascular function in animals, which limits understanding of the 
mechanisms involved.  Several pharmacologic effects are associated with synthetic 
cannabinoids which was determined to induce anxiety in animals. For instance, in rats, it 
contributes to higher serum corticosterone concentrations that directly refer to the aspect 
of being responsive to stress (White, 2017). (Niederhoffer & Szabo, 1999) however, in 
their study they found no evidence for vasodilation in response to WIN 55, 212-2. 
Evidence for PVN in Cardiovascular Control 
The paraventricular nucleus of the hypothalamus (PVN) amongst many other 
functions, is known to regulate the autonomic nervous system by controlling the 
sympathetic outflow to the heart and the blood vessels. Due to its critical role in 
regulating sympathetic tone, dysregulation in sympathetic activity directly correlates to 
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dysregulation of the heart, and in some cases, heart failure. Pre-autonomic neurons of the 
PVN become disinhibited and lead to increased sympathetic activity via glutamate and 
angiotensin II (Pyner, 2014). The PVN plays a critical role in regulating blood volume 
via the mechanoreceptors in the heart. An increase in blood volume stimulates increases 
in heart rate, renal vasodilation via vasopressin neurotransmission, increases in urine 
output, and sodium loss (Dampney, Michelini, Li, & Pan, 2018). It is also known that the 
PVN is critical in chronic stress responses, psychological stress, such as conditioned fear, 
as well as continuous increases in sympathetic nerve activity (Dampney et al., 2018). It is 
known that in spontaneously hypertensive rats, the PVN pre-sympathetic neuronal 
excitement and sympathetic outflow is significantly increased in comparison to 
normotensive rats, such as Sprague Dawley rats. PVN pre-sympathetic neurons are 
critical to increases in sympathetic vasomotor activation that causes increases in blood 
pressure and hypertension (Dampney et al., 2018).  Some work suggests that cannabinoid 
receptors are expressed in the PVN (Grzeda et al., 2015; Ozturk et al., 2019). Thus, the 
PVN may be involved in the cardiovascular responses to synthetic cannabinoids.  
cFos as a Neuronal Marker 
cFos is a gene that is activated through sensory stimulation, as it encodes for the 
Fos transcription factor. The Fos protein is produced in the cytoplasm, then travels to the 
nucleus where it combines with other proteins to create heterodimeric transcription 
complexes in order to regulate transcription of other genes (Kovacs, 2008). Neuronal Fos 
signal activation occurs where the animal is exposed to a novel stimulus for a 90-minute 
period of time. Immunostaining, which is the application of antibodies that work against 
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the desired protein, in this case, cFos protein as a neuronal marker, can be observed 
(Chung, 2015).  
Summary of Rationale 
 
The use of synthetic cannabinoids is prevalent and increasing in some countries. 
Epidemiological data indicate that use of synthetic cannabinoids is associated with 
significant cardiovascular mortality. Data in animals is mixed with some data showing 
decreases in blood pressure and heart rate whereas, other data shows increase in blood 
pressure and heart rate. A major difference occurs between anesthetized and conscious 
animals, suggesting involvement of the brain. CB receptors are extensively distributed in 
the brain and are known to be found in the PVN. 
Statement of Hypothesis 
We hypothesize that the PVN is a site in the brain that synthetic cannabinoids act 
on to cause increased blood pressure by activating the sympathetic autonomic nervous 
system, thereby, wiping out the response by inhibiting neurotransmission. Looking at the 
big picture, this project aims to identify the role of the PVN in the abuse of synthetic 
cannabinoids and how they are associated with cardiovascular adverse effects, so if we 
understand their mechanisms of action, we can figure out effective treatments. 
Specific Aims 
 
1) Determine the blood pressure and heart rate responses to a synthetic cannabinoid, 
WIN 55, 212-2, in conscious rats.  
2) Determine the role of the autonomic nervous system in these responses. 
3) Determine if the hypothalamic paraventricular nucleus is involved in the response 




II. MATERIALS AND METHODS 
 
Animals 
Male Sprague Dawley rats (300-400 grams) from ENVIGO or the Animal 
Resource Center (ARC) 60-90 days old were used. The animals were housed in the ARC 
two per cage, in a room with many other rats. The room is set on a specific light/dark 
cycle, where the lights turn on at 6 am and turn off at 6 pm.  The protocols used were 
approved by the Institutional Animal Care and Use Committee (IACUC) and observed 
NIH guidelines. 
Surgical Interventions 
Male Sprague Dawley rats (300-400 grams) were randomly selected and placed in 
an anesthesia chamber connect to a gas anesthetic (isoflurane) vaporizer.  Isoflurane (5%) 
with an oxygen flow rate of 3 L/min was used to induce anesthesia.  Once the animal had 
lost the righting reflex, the isoflurane was adjusted to 2-3% to maintain anesthesia.  The 
rat was shaved at the surgical locations, the femoral area and the nape of the neck. Each 
surgical area was wiped with iodine scrub (x2) and 70% isopropyl alcohol ending with a 
wipe of regular iodine to disinfect the surgical sites. The rat was then transferred to a 
water jacket heating pad (set at 45 degrees C), taped down in the dorsal recumbent 
position, artificial tears were placed on the eyes, and the rat placed back in the nose cone 
with the isoflurane anesthesia this time at the 2.5 level. Anesthesia was adjusted based on 
need as judged by the respiratory rate or reaction to pinch.  The rat’s tail was labeled with 
indelible marker for permanent identification. The surgical area surrounding the rat was 
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wiped down with 70% isopropyl alcohol.  A surgical pack that had been autoclaved at a 
sterilization temperature of 270 degrees for 20 minutes, with a 15-minute drying time was 
placed next to the surgical area. The rats were covered with a piece of Press and Seal 
wrap (Glad Wrap) to serve as a sterile surgical drape.  The surface was scrubbed with 
70% isopropyl alcohol.  Sterile gloves and a surgical mask were put on, and the surgical 
pack was opened.  
The rats were treated with Buprenorphine SR (1.2 mg/mL/kg) to provide 
analgesia.  A fourth of an inch incision was made through the skin at the femoral area 
vertically towards the midline using scissors. Then, blunt dissection using forceps was 
used to separate tissues until the femoral artery and vein were revealed.  The vessels were 
isolated from each other using blunt dissection with forceps, and a 3-0 black silk non-
absorbable suture was placed around each vessel at both the proximal and distal ends.  
During this process, the area was infiltrated with 2% lidocaine to provide local anesthesia 
and relax the vessels for catheter insertion.  The sutures were first used to occlude the 
flow of the vessels during catheter insertion.  Then a small cut was made on the vessels 
using micro-Vanna spring scissors to introduce the catheters into the vessels.  
Polyethylene Tubing (PE-50) connected to a syringe containing heparinized saline (25 
U/ml) for the venous catheter tubing. The arterial catheter consisted of Tygon microbore 
tubing (0.020”) glued together with a 1” long piece of micro-renathane MRE-025 for the 
intravascular portion. The catheter was glued together days prior to the surgery using 
E6000 to bind it together.  The micro-renathane provided a non-thrombotic surface to 
prolong catheter patency during chronic implantation. The venous and arterial catheters 
were soaked for an hour in iodine and then for an hour in 70% isopropyl alcohol and 
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flushed with heparin saline prior to implantation.  The catheters were then introduced into 
the vessels about 1”, tied in place, then tunneled subcutaneously to the back of the neck 
using a trochar. The femoral area was sutured closed with 4-0 violet braided, polyglycolic 
acid, absorbable suture followed by 2-4 stables and vet bond.  The area at the back of the 
neck was sutured around the catheters with 3-0 black silk non absorbable suture, 
wrapping the catheters around 6 times, and sealed with vet bond to help hold the catheters 
during chronic implantation. The catheters were trimmed to about ¾” sticking out 
between the ears, flushed with heparin saline, and plugged. For plugs, we used a blunted 
and crimped 22 gage hypodermic needle about ¼” long, injected with E6000 glue which 
was allowed to dry a few days prior to surgery to bond and seal. The wounds were 
covered with a topical antibiotic ointment (bacitracin). The rats were returned to their 
home cage. After the rats regained consciousness and were mobile, they were returned to 
the animal quarters to recover.  
Protocol 
The animals were then allowed 3-5 days of recovery, then trained to the recording 
area for 2-3 days. The animals were checked on daily, to assess for general condition, 
mobility, leg functioning, and weight. On the training days, the rats were brought to the 
recording room so they could acclimate to the environment. On the training days, the 
rat’s arterial and venous catheters were flushed with heparin saline to ensure there were 
no clots. On the experimental days, the arterial line was connected to a pressure 
transducer connected to the BioPac recording system where arterial pressure and heart 
rate were recorded continuously.  
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The rationale for the doses of WIN were taken from the literature (S.M. Gardiner, 
2001). The cyclodextrin vehicle is made up from a 20% weight to volume ratio with 
sterile water and then vortexed until into solution. Initially, we attempted 50, 100, and 
300 g/kg doses, but the 300 g/kg had severe adverse behavioral effects, so we switched 
to doses of 25, 50, and 100 g/kg. The WIN was made up by weighing out between 400-
700 micrograms, and then mixed with it 20% Cyclodextrin (vehicle) to make the stock 
solution of 100 g/kg. To go into solution, the 100 g/kg dose of WIN was put in the 
sonicator for about 20 minutes, then placed in a beaker of water on a hot plate at level 8 
for 10 minutes, vortexed, then placed back on the sonicator for 20 minutes. This 
procedure was repeated until the drug went into solution. To make the subsequent doses, 
we used serial dilutions. The 50 g/kg was made from diluting part of the stock solution 
with the vehicle by a one-to-one ratio, then the 25 g/kg was made from diluting part of 
the 50 g/kg with the vehicle by a one-to-one ratio.  
A baseline recording (about 30 minutes to an hour) was obtained, until the rats 
exhibited a calm, stable blood pressure and heart rate. The rats then received an 
intravenous injection of 0.2 mL 20% cyclodextrin vehicle followed by 0.2 mL saline 
flush.  Responses to the vehicle injection were recorded for approximately 20 minutes.  
After this, the rats received injections of 0.2 mL of a synthetic cannabinoid, WIN 55, 
212-2, at the doses of 25, 50, and 100 g/kg, followed by a 0.2 mL saline flush 
monitoring for between 30 minutes to an hour in-between each dose. Blood pressure and 
heart rate were monitored for approximately 20 minutes after each injection.  In all cases, 
blood pressure and heart rate were allowed to return to baseline prior to the next 
injection.   
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Ganglion Block Procedure 
Some of the rats were subjected to ganglionic blockade. After getting a successful 
response from the 3 doses of WIN and allowing blood pressure and heart rate to return to 
baseline, the rats received an intravenous injection of a ganglion blocker. Ganglionic 
blockade was used to assess the role of the autonomic nervous system in the responses to 
WIN injection.  Ganglionic blockade was achieved by intravenous injection of 
chlorisondamine iodide at a dose of 10 mg/kg/0.1ml.  The chlorisondamine was made by 
weighing out an amount of drug based on the animal’s weight and sufficient to make up 
about 0.3-0.4 milliliters of solution (extra to account for amounts lost in the needle hub 
and line).  Chlorisondamine iodide is relatively insoluble in aqueous solutions.  It was 
dissolved by adding the drug powder to the appropriate amount of sterile water in a 
sterile test tube.  The solution was then gently heated on a water bath in 1-minute 
increments with vortexing at each step until the drug went into solution.  Once in 
solution, the chlorisondamine solution was loaded into a 1 ml syringe to deliver the drug 
to the rat.  0.1 mL of solution was delivered intravenously followed by a 0.2 ml saline 
flush. After this injection, the rats were monitored until blood pressure and heart rate 
became stable (roughly 10 minutes) then given an injection of 0.2 mL 100 microgram per 
kilogram WIN 55, 212-2 followed by a 0.2 mL saline flush. The rats were then monitored 
for 30 minutes to observe the effect of WIN after ganglion blockade.  
Brain Collection Procedure 
Immunohistochemistry was used to assess the brain involvement in the responses 
to WIN.  The following procedure was used to collect the brain for this purpose.  The 
animal was injected with either 0.2 mL WIN (100 µg/kg) or 20% cyclodextrin vehicle 
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followed by a 0.2 mL saline flush through the venous catheter then monitored for 90 
minutes. The rats were then anesthetized deeply with urethane chloralose (800 mg/kg: 80 
mg/kg).  After waiting for 15 minutes, deep anesthesia was confirmed by tail pinch. 
Then, the animal was placed in a collection tray in the fume hood. A cut was made at the 
xiphoid process, snipping up on both sides of the diaphragm until the heart was exposed. 
The right atrium was then snipped to release blood, then 40-50 mL of heparin saline was 
injected into the left ventricle to flush the vascular system of blood.  This was followed 
by 40-50 mL of 4% paraformaldehyde for perfusion fixation of the brain.  A big scissor 
was then used to separate the head from the body, the skin on the top of the head was 
peeled back to reveal the skull then a rongeur is used to carefully chip away the skull like 
an eggshell to collect the brain. The brain was then placed in a solution of 4% 
paraformaldehyde for 24 hours for post fixation.  After which the brain was transferred 
for long-term storage to a 20% sucrose solution to cryoprotect the brain in preparation for 
cryosectioning.  
Cryosectioning Procedure 
The cryostat was set to -20 degrees and to cut sections at 30 microns. The frontal 
lobe and the occipital lobe of the brain were then cut off using a razor blade to block the 
brain for mounting on the sectioning pedestals.  The brain was then mounted onto the 
pedestal using Tissue-Tek O.C.T compound and then placed into a bucket of crushed dry 
ice for a few minutes to ensure rapid, complete and uniform freezing. Then, the mounted 
brain was placed into the chuck of the cryostat.  30-micron sections were taken, and the 
chuck adjusted until an even section was obtained.  Sections were discarded until the 
optic chiasm and 3rd ventricle became visible. The sections were then collected, three per 
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slide, from approximately bregma -1.30 to -2.30 mm using anatomical markers (e.g., 
optic chiasm) as depicted in the atlas of Paxinos and Watson. The sections are mounted to 
the slides by carefully placing them on the slide and then placing a warm finger 
underneath so that it would heat up and bind to the slide. The section to slide arrangement 
are as follows: the first slide: sections 1, 4, and 7, second slide: 2, 5, and 8. third slide: 3, 
6, and 9; and so forth.  This staggered order on successive slides was used to allow close 
proximity of sections destined for immunohistochemical and histochemical staining.  
Immunohistochemistry Procedure 
First, a hydrophobic barrier with a Vector laboratories ImmEdgeTM Pen was 
applied around each section on each slide. Then, the sections were subjected to a heat-
induced antigen retrieval protocol as follows. 100 mL of citrate buffer with a pH of 6 was 
boiled for five minutes in a beaker. Then, the tissue slides were placed in a six-well 
plastic slide box and the citrate buffer was poured over the top of the slides, and then 
boiled in the microwave again for seven minutes. After boiling, the plastic slide box was 
immersed in an ice bath for one hour to cool the sections.  
After one hour in the ice bath, the following IHC protocol was performed. The 
slides were washed 5 times each with 1% phosphate buffered saline containing 1% (v/v) 
Tween detergent (PBS-T). The 1% PBS-T is made up of a phosphate buffered saline 
tablet (Sigma P4417) in 200 mL of ultra-pure water and 2 mL Tween 20. Then, the slides 
were placed back into the plastic slide box for application of antibody solutions.  The 
primary antibodies were made in a solution of 10% goat serum in 1% PBS-T.  The 10% 
goat serum in 1% PBS-T is made up of 1 mL Goat Serum in 9 mL 1% PBS-T. The 
primary antibody used was an Abcam rabbit polyclonal to cFos (ab190289) (1mg/ml). 
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For application to the sections, a 1:100 dilution was used by taking 1-part Abcam 
primaries to 99 parts 10% goat serum in 1% PBS-T (10 µL Abcam and 990 µL 10% Goat 
Serum in 1% PBST). For staining, 10 µL of the cFos primary antibody solution was 
placed on the first section and the third section of each slide.  The middle section on each 
slide was used as a primary antibody negative control section.  This section was treated 
with a negative control of 10 µL 10% goat serum in 1% PBS-T which did not contain the 
primary antibody. Then, the plastic slide box was placed in the fridge on the rocker at 4 
degrees Celsius for 24-hours. After 24 to 48 hours, the slides were thoroughly washed 
five times with 1% PBS-T prior to application of the secondary antibody.  The secondary 
antibodies were applied to each of the three sections on the slides. The secondary 
antibodies are made up from a donkey or goat anti-rabbit highly cross-absorbed 
secondary antibody, Alexa Fluor Pluss 488 (2 mg/mL) Invitrogen (donkey: A32766, 
goat: A32731).  10 µL of the anti-donkey or anti-goat secondary antibody was diluted in 
1990 µL of 10% goat serum in PBST. 10 µLs was then applied to each section on the 
slide.  The slides were then left in a covered box for two hours at room temperature for 
incubation and to protect from light since the fluorescent antibodies are subject to 
photobleaching.  After two hours incubating in the secondary antibodies, the slides are 
thoroughly washed five times with 1% PBS-T and then a coverslip mounting medium 
containing 4′,6-diamidino-2-phenylindole, DAPI (to visualize nuclei) was placed on each 
of the sections on the slide, and then a dust-free coverslip was placed over the top. The 
slides were stored in the covered opaque box in the fridge at 4 degrees Celsius for 40 




Cresyl Violet Staining Procedure 
Cresyl violet stains the DNA and RNA nucleic acids in the brain in order to detect 
the shapes of the structures in the brain. Slides adjacent to the ones we ran for the 
immunohistochemistry procedure were then taken for cresyl violet staining, to confirm 
the location of the PVN. The cresyl violet stock solution is made up of 0.2 grams cresyl 
violet-acetate with 150 mL distilled water, then mixed with a stir bar for 20 minutes. The 
buffer solution (pH 3.5) was made from 282 mL of 0.1 M acetic acid (6 mL concentrated 
acetic acid per 1000 mL distilled water) with 18 mL of 0.1 M sodium acetate (13.6 grams 
in 1000 mL distilled water). Then, 30 mL of cresyl violet stock solution with 300 mL of 
buffer were mixed for 30 minutes. First, the slides were placed in Xylene for 5 minutes, 
then 95% isopropyl alcohol for 3 minutes, then 70% isopropyl alcohol for 3 minutes, then 
deionized distilled water for 3 minutes, then cresyl violet for 8 minutes, distilled water for 
3 minutes, 70% isopropyl alcohol for 3 minutes, 95% alcohol for 1 minute, then one dip 
of 100% isopropyl alcohol, then HemoD for 5 minutes, then Citrisol for up to 24 hours. 
Then, the slides were cover slipped with a histological mounting medium and left 
overnight to dry before observing under the microscope.  
Fluorescent Microscopy 
A Leica DMLB microscope with Leica Application Suite X software was used for 
the fluorescent microscopy procedure. An emission wavelength of 488 was used to 
visualize cFos under the microscope and the DAPI channel was used to get emission at 
wavelength of 461 fluorescence for DAPI.  Images were taken for the WIN injected 
brain’s as well as the vehicle injected brains at 10x, 20x, and 40x of both 488 and DAPI 
for the PVN area with and without primary antibodies, the Amygdala area with and 
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without primary antibodies. At least 24 images per slide were collected. The cFos 
staining with the DAPI staining at each magnification level for each location were then 
overlayed to identify if the perceived cFos staining was within the nuclei. Then, the 
cresyl violet slides were observed through light/bright field under the microscope at 5x 
magnification and images were taken at both the PVN and Amygdala for each slide. 
III. DATA ANALYSIS 
Blood Pressure and Heart Rate Data 
The blood pressure and heart rate data were analyzed from each tracing by 
measuring the baseline blood pressure and heart rate before each injection, then the blood 
pressure and heart rate for one-minute durations every five minutes post injection to 
obtain the time course of each response.  The peak heart rate and blood pressure to each 
of the doses of WIN injection were also collected for a one-minute duration. Once 
acquiring these data were compiled into Excel spreadsheets and transferred to an analysis 
package (GraphPad Prism) for analysis.  Data was checked for outliers using Grubb’s 
test.  One blood pressure data point was removed since it tested out to be an outlier.  Data 
that did not meet criteria for parametric analysis were log transformed prior to analysis.   
Image J Analysis of Immunofluorescence Images 
 
TIFF images of the overlay for cFos and DAPI staining were imported into NIH 
Image J. These color images were then separated into their red (nonexistent), green 
(cFos) and blue (DAPI) component channels. Background subtraction was performed on 
each channel. The threshold feature of Image J was then used to despeckle the images. 
An area encompassing the region of interest (PVN or Amygdala) was defined using the 
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polygon tool on Image J. The bounded area was then analyzed using the analyze particle 
function from the analysis menu. This produced an output that included the number of 
particles (counts). Matched areas were used to analyze the green (cFos) and blue (DAPI) 
channels. The particle counts from each analysis was entered into an Excel spreadsheet. 
cFos staining was expressed as a proportion of overall cell number in the selected area as 
reflected by the DAPI particle counts (% cFos staining = (cFos particle count/DAPI 
particle count) x 100). Staining was evaluated on the sections with and without primary 





Effect of WIN 55, 212-2 on blood pressure and heart rate in conscious rats.  
Raw tracings for blood pressure and heart rate are shown in figure 6.  Briefly, 
cyclodextrin vehicle did not appear to affect blood pressure or heart rate whereas WIN 
injection increased both blood pressure and heart rate.  Summary data are presented in 
figures 7 and 8.  Baseline blood pressure and heart rate averaged approximately 122 4 
mm Hg and 356 11 bpm prior to the injection of the cyclodextrin vehicle.  Injection of 
cyclodextrin vehicle caused changes in blood pressure 0.2 1 mm Hg and heart rate -1 2 
bpm that were not significantly different from baseline.  In contrast, intravenous injection 
 
Figure 6.  This figure shows real time tracings for arterial blood pressure (top tracing in each 
panel) and heart rate (lower tracing in each panel) before and during injection of 
cyclodextrin vehicle (top left) and WIN 55, 212-2 in increasing doses of 25, 50 and 100 µg/kg.  
Vehicle injection did not markedly affect blood pressure or heart rate.  Injection of WIN 
increased both blood pressure and heart rate. 
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of WIN produced markedly different effects.  These data are illustrated in figures 6 
(MAP) and 7 (HR).  At the lowest dose of 25 µg/kg, blood pressure increased by 7 2 
mm Hg while heart rate increased by 30 7 bpm.  At the middle dose of 50 µg/kg, these 
responses were 163 mm Hg and 5813 bpm.  At our highest dose of 100 µg/kg, we 
observed an increase of 18 2 mm Hg in blood pressure, and 74 10 bpm in heart rate.  
These responses were significantly greater than that caused by vehicle injection.  
Therefore, intravenous injection of WIN was associated with dose dependent increases in 



























Figure 7.  This figure shows the changes in mean arterial pressure obtained in 
conscious rats (n=10-11) injected with vehicle (0) or incremental doses of a 
synthetic cannabinoid, WIN 55, 212-2 at doses of 25, 50 and 100 µg/kg. 
ANOVA followed by Dunnett’s Test. * Indicates significant difference from 



















We also measured the MAP and HR responses for 20 minutes after injection to 
establish a time course.  The data are shown in figures 9 (MAP) and 10 (HR).  As shown 
in figure 9, the blood pressure response reached its highest point within the first 5 minutes 
after injection and then declined thereafter.  However, blood pressure remained 
significantly elevated compared to vehicle injection up to the 15-minute mark.  At the 
lowest dose, blood pressure was no longer significantly higher than vehicle injection at 20 
minutes post injection.  As might be expected, higher doses had longer durations and the 
blood pressure responses to WIN remained significantly above those for vehicle even after 
20 minutes.   
 
 
Figure 8.  This figure shows the changes in heart rate obtained in conscious rats  
(n=10-11) injected with vehicle (0) or incremental doses of a synthetic cannabinoid, 
WIN 55, 212-2 at doses of 25, 50 and 100 µg/kg.  ANOVA followed by Dunnett’s Test. 





A somewhat similar pattern was observed in terms of heart rate.  WIN injection 
produced very rapid onset increases in heart rate that appeared to peak at around 5 minutes 
post injection.  Somewhat different from blood pressure however, heart rate did not rapidly 









Figure 9.  This figure shows the time course of the changes in blood pressure obtained 
in conscious rats (n=10) injected with vehicle or incremental doses of a synthetic 
cannabinoid, WIN 55, 212-2 at doses of 25, 50 and 100 ug/kg.  Repeated measures 
ANOVA followed by Student Newman Keul test. * p<0.05 vehicle vs 25 ug/kg, Ф 



















Effect of Ganglion Blockade 
The cardiovascular responses to synthetic cannabinoids may involve an 
autonomic nervous system component.  We used pharmacological ganglion blockade to 
assess the role of the autonomic nervous system.  Ganglion blockers work by blocking 
the transmission at the sympathetic and parasympathetic ganglia in the autonomic 
nervous system. Administration of the ganglion blocking agent, chlorisondamine, 
reduced both blood pressure (1205 to 804 mm Hg) and heart rate (38112 to 34517 
bpm). Figure 10 shows compares the MAP and HR responses to WIN 100 µg/kg obtained 
before and after ganglionic.  This data shows that Synthetic Cannabinoid, WIN, acts by 
 
 
Figure 10.  This figure shows the time course of the changes in heart rate 
obtained in conscious rats (n=10) injected with vehicle or incremental doses of a 
synthetic cannabinoid, WIN 55, 212-2 at doses of 25, 50 and 100 µg/kg.  
Repeated measures ANOVA followed by Student Newman Keul test. * p<0.05 





increasing sympathetic outflow. Pre-ganglionic blockade, we observed a change in mean 
arterial blood pressure of 17 2 and change in heart rate of 63 9. Post ganglionic 
blockade, we observed a MAP response of 1 2 mm Hg and a HR response of -13 5 
























We used cFos immunohistochemistry as an approach to detect neuronal activation 
in response to drug injection.  Each immunohistochemistry run included a section in 
which no primary antibody was included.  This section served as an antibody negative 
control as illustrated in figure 12.   Very little punctate green (cFos) staining was 
observed in these sections indicating little to no non-specific binding of the fluorescent 
secondary antibody.   
 
Figure 11.  This figure shows the effect of autonomic blockade on blood pressure and 
heart rate obtained in conscious rats (n=6) injected with synthetic cannabinoid, WIN 
55, 212-2 at a dose 100 µg/kg. Paired t-test. * Indicates significant difference from 














Two animals received vehicle injection prior to brain collection and served as 
vehicle controls for immunohistochemistry.  The results from these two rats were 
variable as illustrated in figure 13.  In one case there was some positive cFos staining 
observed as depicted in figure 12.  This staining was relatively sparsely distributed but 
appeared to be localized primarily along the lower ventricular margin of the PVN.  In the 
other vehicle injected rat, no staining was observed in the PVN.  
 
Figure 12. This figure shows fluorescent immunohistochemistry images for cFos (green) 
and DAPI staining in a section where the primary antibody to cFos was omitted.  These 
sections served as antibody negative controls.  From the top left shows 488 emissions, 
then DAPI staining (top right), overlay of 488 and DAPI low power (bottom left) and high 
power (bottom middle).  The lower right shows a cresyl violet image to identify location. 
There is virtually no green punctate staining indicating that there was very little 
nonspecific binding of the secondary antibody. Scale bars are shown in each figure.  3rd V 




WIN injection was associated with an increase in cFos staining.  An 
example of this staining is shown in figure 14.  Punctate green staining was 
observed in the region of the PVN in discrete cells.  DAPI overlay was consistent 
with the idea that this staining occurred in the nucleus, consistent with cFos 
staining.  The cresyl violet (Nissl stain) image shows that this section was taken in 






Figure 13. This figure shows fluorescent immunohistochemistry images for cFos (green) and 
DAPI (blue) staining in a section where the rat was injected with cyclodextrin vehicle.  From 
the top left shows 488 emissions, then DAPI staining (top right), overlay of 488 and DAPI low 
power (bottom left) and high power (bottom middle).  The lower right shows a cresyl violet 
image to identify location.  Some positive cFos staining was observed with as indicated by 





 Summary data for PVN cFos staining is shown in figure 15.  These data 
are expressed as the proportion of cFos positive cells to DAPI positive cell counts.  
Virtually no staining consistent with cFos staining was observed in the antibody 
negative control sections (0.60.4%).  Vehicle injection was associated with a 
small but observable increase in the proportion of cells exhibiting cFos staining in 
the PVN region (31%).  WIN injection also elicited an increase in the proportion 
of cells staining positive for cFos in the PVN region (92%).  The WIN induced 
increase in cFos staining was significantly greater than that observed for either 
antibody negative control or vehicle control.  
 
Figure 14. Composite immunohistochemistry images of the PVN from a WIN injected rat, at 
10x using Leica DMLB microscope with Leica Application Suite X software. Top left: cFos 
staining observed at emission wavelength of 488.  Note the punctate green staining absent in 
the antibody negative control sections in figure 12.  Top right: DAPI staining observed at 
emission wavelength of 461. Bottom left: Overlay of cFos and DAPI at 10x magnification. 
Bottom middle is overlay at 20x. Scale bars are shown in the figures.  Bottom right: Cresyl 





Although not part of our overall hypothesis, we also observed increases in cFos 
staining a region ventral and lateral to the PVN.  This area corresponds to an area 
described as the medial amygdaloid nucleus in the atlas of Paxinos and Watson 
(figure 16).   
 
Figure 15.  This figure shows the counts of cFos staining in percent DAPI at the PVN with no 
primary (n=5), animals treated with vehicle only (n=2), and animals treated with WIN 55, 
212-2 (n=5).  ANOVA followed by Student Newman Keul test. * Indicates significant 






Figure 17 shows images for staining observed in an antibody negative control 
section in the region of the MeAD.   Very little punctate green (cFos) staining was 
observed in these sections indicating little to no non-specific binding of the 





Figure 16.  Image of the coronal section from the atlas of Paxinos and Watson shown a 
coronal section through the brain region where we detected positive cFos staining 





As observed with the PVN, vehicle injection appeared to increase positive 
cFos staining in the MeAD region as well as shown in figure 18.  cFos staining was 
relatively sparsely distributed through this region.  Nevertheless, high power 
examining did show nice overlay of the green and blue staining consistent with 






Figure 17.  This figure shows fluorescent immunohistochemistry images for cFos (green) and 
DAPI (blue) staining in a section where the primary antibody to cFos was omitted.  These 
sections served as antibody negative controls.  From the top left shows 488 emissions, then 
DAPI staining (top right), overlay of 488 and DAPI low power (bottom left) and high power 
(bottom middle).  The lower right shows a cresyl violet image to identify location. There is 
virtually no green punctate staining indicating that there was very little non-specific binding 







WIN injection was also associated with an increase in positive cFos staining in the 
MeAD region. An example of this staining is shown in figure 19.  Punctate green 
staining was observed in discrete cells.  DAPI overlay was consistent with the idea that 
this staining occurred in the nucleus, consistent with cFos staining.  Visually this 
staining appeared to be denser than that produced by vehicle injection.  The cresyl 
violet (Nissl stain) image shows that this section was taken in the Medial Amygdaloid 
Nucleus.   
Summary data for Amygdala cFos staining is shown in figure 20.  These data are 
expressed as the proportion of cFos positive cells to DAPI positive cell counts.  
 
Figure 18.  This figure shows fluorescent immunohistochemistry images for cFos (green) 
and DAPI (blue) staining in a section where the rat was injected with cyclodextrin vehicle.  
From the top left shows 488 emissions, then DAPI staining (top right), overlay of 488 and 
DAPI low power (bottom left) and high power (bottom middle).  The lower right shows a 
cresyl violet image to identify location.  Some positive cFos staining was observed with as 




Virtually no staining consistent with cFos staining was observed in the antibody 
negative control sections 
 
 
(0.360.17%).  Vehicle injection was associated with a small but observable 
increase in the proportion of cells exhibiting cFos staining in the Amygdala region 
(4.51.8%).  WIN injection also elicited an increase in the proportion of cells 
staining positive for cFos in the amygdala region (225%).  The WIN induced 
increase in cFos staining was significantly greater than that observed for either 
antibody negative control. 
 
Figure 19. Composite immunohistochemistry images of Amygdala observed in a rat that 
received WIN 55, 212-2 injection. Magnification at 10x using Leica DMLB microscope with 
Leica Application Suite X software. Top left: cFos staining observed at emission 
wavelength of 488. Note the punctate green staining absent in the antibody negative 
control sections in figure 17. Top right: DAPI staining observed at emission wavelength 
of 461. Bottom left: Overlay of cFos and DAPI at 10x magnification. Bottom middle is 
overlay at 20x. Scale bars are shown in the figures.  Bottom right: Cresyl Violet Staining 













Figure 20.  This figure shows the counts of cFos staining in percent DAPI at the 
Amygdala with no primary (n=5), animals treated with vehicle only (n=2), and 
animals treated with WIN 55, 212-2 (n=5). ANOVA followed by Student Newman 






In our study of the hemodynamic responses to WIN 55, 212-2, we saw dose 
dependent increases in blood pressure and heart rate. At our highest dose of WIN 55, 
212-2, 100 µg/kg, we observed an increase of 18±2 mm Hg in blood pressure, and 74 ±10 
bpm in heart rate. (Schindler et al., 2017) used several other synthetic cannabinoids: 
JWH-018 AM2201, XLR-11, CP55, 940. They saw dose dependent increases in blood 
pressure with peak changes of about 15 mm Hg. Our findings using WIN 55, 212-2 are 
consistent with this, as we saw changes in blood pressure of about 18 mm Hg. A pressor 
response appears to be a general feature of synthetic cannabinoids, as all of them increase 
blood pressure in conscious rats. As an example, (Schindler et al., 2017) found that CP55, 
940, JWH-018, and AM2201, and XLR-11 produced a hypertensive effect. The literature 
is consistent with our findings on synthetic cannabinoids in blood pressure. In contrast, 
(Schindler et al., 2017) found no change in heart rate, where we observed significant dose 
dependent increases in heart rate. It is difficult to reconcile these opposing findings. 
However,  (Schindler et al., 2017) used subcutaneous injection, where we used direct 
intravenous injection, which may have allowed greater access of the drugs to the brain.  
Also, in contrast to our findings, (Niederhoffer & Szabo, 1999) reported that 
intravenous injection of WIN 55, 212-2 acts to decrease blood pressure and heart rate in 
conscious rabbits. They ascribed this to peripheral sympathetic inhibition. These 
differences are difficult to explain but may be due to the difference in species used. In 
addition, (Malinowska et al., 2012) summarized the effects of various synthetic 
cannabinoids on blood pressure and heart rate as seen in the literature, which 
overwhelmingly suggests that there is a difference in response that is seen upon 
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administration of a synthetic cannabinoid in conscious animals versus anesthetized 
animals. In conscious animals, synthetic cannabinoids are widely reported to produce 
increases in blood pressure and heart rate, whereas in anesthetized animals, decreases are 
seen. As an example, (Kristy D. Lake, 1997) reported dose dependent decreases in mean 
arterial pressure and heart rate, but their work used urethane chloralose anesthetized rats. 
(Malinowska et al., 2012) confirmed the marked distinction between conscious and 
anesthetized responses. As referenced in figure 5, this is important, since humans use the 
drug while they are conscious, and the human data shows tachycardia and hypertension. 
The data for conscious responses is more relevant to what is seen in humans. Our data is 
consistent with the responses seen in humans.  
The hypertensive effects of synthetic cannabinoids are an opposing response than 
what seen in cannabis. Although there have been some conflicting reports, the bulk of the 
evidence suggests that THC seems to lower blood pressure and produce bradycardia in 
both conscious and anesthetized animals, as well as in humans (Sultan, Millar, 
O'Sullivan, & England, 2018). This reinforces the view that while they presumably act on 
the same system, synthetic cannabinoids produce markedly different responses than 
synthetic cannabinoids.  
(López-Dyck et al., 2017; Spiller et al., 2019) studied the expression of CB1 and 
CB2 receptors in the vasculature using two synthetic cannabinoids, ACPA, and JWH-
133. They looked at what the effects of these synthetic cannabinoids did on each receptor 
in terms of vascular tone. They found that if you activate CB1 or CB2 receptors, you get 
vascular dilation, which lowers blood pressure and heart rate (López-Dyck et al., 2017). 
However, we saw increases in blood pressure and heart rate, our findings suggest that the 
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increased blood pressure and heart rate are occurring due to a mechanism within the 
brain.  
There are cannabinoid receptors located all throughout the different regions of the 
brain. (Spiller et al., 2019) found that CB1 and CB2 receptors are expressed both in the 
vasculature, as well as in the reward and aversion centers of the brain, including the 
ventral tagmental area and the nucleus acumbens. The CB1 receptors in the PVN have 
been shown to affect cardiovascular responses, as Grezda (Grzeda et al., 2015) saw that 
upon microinjection of a CB1 receptor antagonist into the PVN, then injection of CP55, 
940 into the PVN, stimulation of CB2 receptors in the PVN caused increases in blood 
pressure and heart rate. In addition, lesions of the PVN abolished their responses to 
intravenous injection of CP55, 940.  
Prior work has shown that autonomic blockade attenuates the responses to 
synthetic cannabinoids, (S.M. Gardiner, 2001) and (Schindler et al., 2017). We injected 
chlorisondamine iodide prior to injection of our highest dose of WIN, 100 µg/kg to block 
autonomic functioning to determine if the sympathetic nervous system is involved in the 
mechanism of increased blood pressure and heart rate seen when injecting WIN 55, 212-
2. Our findings show that injection of ganglionic blocker prior to injection of WIN 55, 
212-2 completely blocks the effect of WIN. The literature supports our findings that the 
autonomic nervous system mediates the cardiovascular effects of WIN 55, 212-2. 
Gardiner used pentolinium for a ganglion blocker and found that it antagonized the 
pressor effect of WIN (S.M. Gardiner, 2001). (Schindler et al., 2017) found that 
pretreatment of hexamethonium as a ganglion blocker, antagonizes the increased blood 
pressure and heart rate responses seen using two other synthetic cannabinoids. Our work 
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is consistent with that found in the literature. Under our conditions, with our animals, 
using WIN 55, 212-2, we have determined that it appears the increases in blood pressure 
and heart rate caused by WIN is mediated through the brain via the autonomic nervous 
system. Possibly, the reason others have reported seeing vasodilator effects, is because of 
the study done by (Niederhoffer & Szabo, 1999) that shows that it actually blocks the 
release of norepinephrine, but maybe that is overcome by the central nervous system, so 
when we block the nerves at the ganglia, there is no norepinephrine to block to prevent 
release, so that is why we did not see that effect in our responses.  
The current literature in combination with our findings suggest that synthetic 
cannabinoids cause a sympathetic pressor effect via the brain, when administered within 
conscious animals. When injected prior to WIN 55, 212-2; the chlorisondamine iodide 
(10 mg/kg/0.1 mL) blocks the effect of WIN 55, 212-2 on the rest of the system, 
suggesting that the autonomic nervous system is involved. The PVN is involved in 
autonomic control (Dampney et al., 2018; Pyner, 2014). Injection of synthetic 
cannabinoids into the PVN increases blood pressure and heart rate (Grzeda et al., 2015).  
We used cFos immunohistochemistry, to assess brain involvement, focusing on 
the PVN. In our study, even though we did see cFos staining within the vehicle, 
specifically within the PVN and amygdala (figure 18). WIN produced a much stronger 
increase in cFos staining (figure 15, figure 20) than the vehicle in both the PVN and 
Amygdala. Any effect of the vehicle seen in the PVN, and Amygdala are likely due to 
handling or stress. The PVN is involved in autonomic control, blood pressure and heart 
rate responses (Dampney et al., 2018), and has CB receptors (Grzeda et al., 2015), so it is 
logical to conclude that the PVN is part of the circuitry involved in the blood pressure 
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and heart rate response, as we saw. Stimulation of the amygdala causes many 
physiological responses including negative emotions, anxiety, stress, increases in 
sympathetic nervous system activation, and increases in blood pressure and heart rate 
(Kraynak, Marsland, & Gianaros, 2018). Some reports have suggested that CB receptors 
are found in the amygdala (Katona, 2001). So, it seems reasonable to suggest that the 
amygdala is involved in the responses that we saw. Since cFos is a marker of neuronal 
activation, our results suggest that the PVN and the Amygdala are both involved in the 
mechanism of the hypertensive and tachycardic cardiovascular responses we saw in 
response to WIN 55, 212-2.  
VI. CONCLUSION 
Our data is consistent with the view that synthetic cannabinoids increase blood 
pressure and heart rate via the autonomic nervous system to adversely affect the 
cardiovascular system. The immunohistochemistry showed cFos activation within the 
PVN and the Amygdala, which suggests that the brain is involved in the cardiovascular 
effect of synthetic cannabinoid, WIN 55, 212-2. In the human data, increases in heart rate 
are the most frequent response seen, followed by increases in blood pressure being 
second, as seen in figure 5. Cardiovascular adverse effects are the most common response 
to synthetic cannabinoids, as seen in figure 4. Human causes of death upon consumption 
of synthetic cannabinoids are as a result of the severe cardiovascular responses. More 
research to explore the underlying mechanisms may lead to better treatment options for 
the adverse effects of synthetic cannabinoids.  
Further research is needed to prove the linkage between these processes. Going 
forward, we would like to investigate the causal link between the cardiovascular 
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responses to WIN and PVN. We would like to block the amygdala as well as the PVN to 
see if the cardiovascular responses go away. Blocking the CB1 and then the CB2 
receptors in the PVN to see if it changes response. Another option would be to block the 
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